-
1
-
-
0025805153
-
Channeling bias in the interpretation of drug effects
-
Apr;
-
Petri H, Urquhart J. Channeling bias in the interpretation of drug effects. Stat Med 1991 Apr; 10 (4): 577-81
-
(1991)
Stat Med
, vol.10
, Issue.4
, pp. 577-581
-
-
Petri, H.1
Urquhart, J.2
-
2
-
-
0030760118
-
A study of the longitudinal utilization and switching-patterns of non-steroidal anti-inflammatory drugs using a pharmacy based approach
-
Jul;
-
Sift R, van Staa TP, Abenhaim L, et al. A study of the longitudinal utilization and switching-patterns of non-steroidal anti-inflammatory drugs using a pharmacy based approach. Pharmacoepidemiol Drug Saf 1997 Jul; 6 (4): 263-8
-
(1997)
Pharmacoepidemiol Drug Saf
, vol.6
, Issue.4
, pp. 263-268
-
-
Sift, R.1
van Staa, T.P.2
Abenhaim, L.3
-
3
-
-
0026644458
-
Channelling of controlled release formulation of ketoprofen (Oscorel) in patients with history of gastrointestinal problems
-
Aug;
-
Leufkens HG, Urquhart J, Stricker BH, et al. Channelling of controlled release formulation of ketoprofen (Oscorel) in patients with history of gastrointestinal problems. J Epidemiol Community Health 1992 Aug; 46 (4): 428-32
-
(1992)
J Epidemiol Community Health
, vol.46
, Issue.4
, pp. 428-432
-
-
Leufkens, H.G.1
Urquhart, J.2
Stricker, B.H.3
-
4
-
-
0034083748
-
The incidence of adverse events and risk factors for upper gastrointestinal disorders associated with meloxicam use amongst 19,087 patients in general practice in England: Cohort study
-
Jul;
-
Martin RM, Biswas P, Mann RD. The incidence of adverse events and risk factors for upper gastrointestinal disorders associated with meloxicam use amongst 19,087 patients in general practice in England: cohort study. Br J Clin Pharmacol 2000 Jul; 50 (1): 35-42
-
(2000)
Br J Clin Pharmacol
, vol.50
, Issue.1
, pp. 35-42
-
-
Martin, R.M.1
Biswas, P.2
Mann, R.D.3
-
5
-
-
0041885420
-
Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs
-
Sep;
-
MacDonald TM, Morant SV, Goldstein JL, et al. Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs. Gut 2003 Sep; 52 (9): 1265-70
-
(2003)
Gut
, vol.52
, Issue.9
, pp. 1265-1270
-
-
MacDonald, T.M.1
Morant, S.V.2
Goldstein, J.L.3
-
7
-
-
0031004839
-
Channeling of three newly introduced antidepressants to patients not responding satisfactorily to previous treatment
-
Jun;
-
Egberts AC, Lenderink AW, de Koning FH, et al. Channeling of three newly introduced antidepressants to patients not responding satisfactorily to previous treatment. J Clin Psychopharmacol 1997 Jun; 17 (3): 149-55
-
(1997)
J Clin Psychopharmacol
, vol.17
, Issue.3
, pp. 149-155
-
-
Egberts, A.C.1
Lenderink, A.W.2
de Koning, F.H.3
-
8
-
-
0023077226
-
Non-steroidal anti-inflammatory drugs: Assessment of risks
-
Inman WH. Non-steroidal anti-inflammatory drugs: assessment of risks. Eur J Rheumatol Inflamm 1987; 8 (1): 71-85
-
(1987)
Eur J Rheumatol Inflamm
, vol.8
, Issue.1
, pp. 71-85
-
-
Inman, W.H.1
-
9
-
-
0035833502
-
The coxibs, selective inhibitors of cyclooxygenase-2
-
Aug 9;
-
FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001 Aug 9; 345 (6): 433-42
-
(2001)
N Engl J Med
, vol.345
, Issue.6
, pp. 433-442
-
-
FitzGerald, G.A.1
Patrono, C.2
-
10
-
-
22244446152
-
The trade-off between cardiovascular and gastrointestinal effects of rofecoxib
-
Jul;
-
Florentinus SR, Heerdink ER, de BA, et al. The trade-off between cardiovascular and gastrointestinal effects of rofecoxib. Pharmacoepidemiol Drug Saf 2005 Jul; 14 (7): 437-41
-
(2005)
Pharmacoepidemiol Drug Saf
, vol.14
, Issue.7
, pp. 437-441
-
-
Florentinus, S.R.1
Heerdink2
ER, D.B.3
-
11
-
-
1542516241
-
Uptake of COX-2 selective inhibitors and influence on NSAID prescribing in Northern Ireland
-
Mar;
-
Girvin B, Rafferty T, Stevenson MR, et al. Uptake of COX-2 selective inhibitors and influence on NSAID prescribing in Northern Ireland. Pharmacoepidemiol Drug Saf 2004 Mar; 13 (3): 153-7
-
(2004)
Pharmacoepidemiol Drug Saf
, vol.13
, Issue.3
, pp. 153-157
-
-
Girvin, B.1
Rafferty, T.2
Stevenson, M.R.3
-
12
-
-
2342489871
-
Upper gastrointestinal bleeding associated with the use of NSAIDs: Newer versus older agents
-
Laporte JR, Ibanez L, Vidal X, et al. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf 2004; 27 (6): 411-20
-
(2004)
Drug Saf
, vol.27
, Issue.6
, pp. 411-420
-
-
Laporte, J.R.1
Ibanez, L.2
Vidal, X.3
-
13
-
-
28544433318
-
Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: Population based nested case-control analysis
-
Dec 3;
-
Hippisley-Cox J, Coupland C, Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005 Dec 3; 331 (7528): 1310-6
-
(2005)
BMJ
, vol.331
, Issue.7528
, pp. 1310-1316
-
-
Hippisley-Cox, J.1
Coupland, C.2
Logan, R.3
-
14
-
-
0034707105
-
-
Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000 Nov 23; 343 (21): 1520-8, 2
-
Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000 Nov 23; 343 (21): 1520-8, 2
-
-
-
-
15
-
-
31044441042
-
Biological basis for the cardiovascular consequences of COX-2 inhibition: Therapeutic challenges and opportunities
-
Jan;
-
Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006 Jan; 116 (1): 4-15
-
(2006)
J Clin Invest
, vol.116
, Issue.1
, pp. 4-15
-
-
Grosser, T.1
Fries, S.2
FitzGerald, G.A.3
-
16
-
-
14844337012
-
Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure
-
Mar 14;
-
Aw TJ, Haas SJ, Liew D, et al. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005 Mar 14; 165 (5): 490-6
-
(2005)
Arch Intern Med
, vol.165
, Issue.5
, pp. 490-496
-
-
Aw, T.J.1
Haas, S.J.2
Liew, D.3
-
17
-
-
0036140865
-
Incidence of serious upper gastrointestinal bleeding/perforation in the general population: Review of epidemiologic studies
-
Feb;
-
Hernandez-Diaz S, Rodriguez LA. Incidence of serious upper gastrointestinal bleeding/perforation in the general population: review of epidemiologic studies. J Clin Epidemiol 2002 Feb; 55 (2): 157-63
-
(2002)
J Clin Epidemiol
, vol.55
, Issue.2
, pp. 157-163
-
-
Hernandez-Diaz, S.1
Rodriguez, L.A.2
-
19
-
-
2542477738
-
Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs
-
May;
-
Zhao SZ, Wentworth C, Burke TA, et al. Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs. Pharmacoepidemiol Drug Saf 2004 May; 13 (5): 277-87
-
(2004)
Pharmacoepidemiol Drug Saf
, vol.13
, Issue.5
, pp. 277-287
-
-
Zhao, S.Z.1
Wentworth, C.2
Burke, T.A.3
-
20
-
-
12444258696
-
National trends in cyclooxygenase-2 inhibitor use since market release: Nonselective diffusion of a selectively cost-effective innovation
-
Jan 24;
-
Dai C, Stafford RS, Alexander GC. National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation. Arch Intern Med 2005 Jan 24; 165 (2): 171-7
-
(2005)
Arch Intern Med
, vol.165
, Issue.2
, pp. 171-177
-
-
Dai, C.1
Stafford, R.S.2
Alexander, G.C.3
-
21
-
-
27644498521
-
Frequent prescribing of drugs with potential gastrointestinal toxicity among continuous users of non-steroidal anti-inflammatory drugs
-
Jul;
-
Helin-Salmivaara A, Huupponen R, Virtanen A, et al. Frequent prescribing of drugs with potential gastrointestinal toxicity among continuous users of non-steroidal anti-inflammatory drugs. Eur J Clin Pharmacol 2005 Jul; 61 (5-6): 425-31
-
(2005)
Eur J Clin Pharmacol
, vol.61
, Issue.5-6
, pp. 425-431
-
-
Helin-Salmivaara, A.1
Huupponen, R.2
Virtanen, A.3
-
22
-
-
33644651336
-
Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: A population-based case-control study
-
Moride Y, Ducruet T, Boivin JF, et al. Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study. Arthritis Res Ther 2005; 7 (2): R333-42
-
(2005)
Arthritis Res Ther
, vol.7
, Issue.2
-
-
Moride, Y.1
Ducruet, T.2
Boivin, J.F.3
-
23
-
-
1942470118
-
COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: A population-based case-control study
-
Apr 1;
-
Norgard B, Pedersen L, Johnsen SP, et al. COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case-control study. Aliment Pharmacol Ther 2004 Apr 1; 19 (7): 817-25
-
(2004)
Aliment Pharmacol Ther
, vol.19
, Issue.7
, pp. 817-825
-
-
Norgard, B.1
Pedersen, L.2
Johnsen, S.P.3
-
24
-
-
2442438559
-
Impact of selective cyclooxygenase-2 inhibitors on anti-ulcer medication and non-steroidal anti-inflammatory drug use in patients with rheumatic disease
-
Apr;
-
Joshua FF, Oakley SP, Major GA. Impact of selective cyclooxygenase-2 inhibitors on anti-ulcer medication and non-steroidal anti-inflammatory drug use in patients with rheumatic disease. Intern Med J 2004 Apr; 34 (4): 153-61
-
(2004)
Intern Med J
, vol.34
, Issue.4
, pp. 153-161
-
-
Joshua, F.F.1
Oakley, S.P.2
Major, G.A.3
-
25
-
-
33747874024
-
Channeling and prevalence of cardiovascular contraindications in users of cyclooxygenase 2 selective nonsteroidal antiinflammatory drugs
-
Aug 15;
-
Mosis G, Stijnen T, Castellsague J, et al. Channeling and prevalence of cardiovascular contraindications in users of cyclooxygenase 2 selective nonsteroidal antiinflammatory drugs. Arthritis Rheum 2006 Aug 15; 55 (4): 537-42
-
(2006)
Arthritis Rheum
, vol.55
, Issue.4
, pp. 537-542
-
-
Mosis, G.1
Stijnen, T.2
Castellsague, J.3
-
26
-
-
33646235891
-
Linking community pharmacy dispensing data to prescribing data of general practitioners
-
Florentinus SR, Souverein PC, Griens FA, et al. Linking community pharmacy dispensing data to prescribing data of general practitioners. BMC Med Inform Decis Mak 2006; 6: 18
-
(2006)
BMC Med Inform Decis Mak
, vol.6
, pp. 18
-
-
Florentinus, S.R.1
Souverein, P.C.2
Griens, F.A.3
-
27
-
-
0002656782
-
Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs
-
Jan 12;
-
Garcia Rodriguez LA, Cattaruzzi C, Troncon MG, et al. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med 1998 Jan 12; 158 (1): 33-9
-
(1998)
Arch Intern Med
, vol.158
, Issue.1
, pp. 33-39
-
-
Garcia Rodriguez, L.A.1
Cattaruzzi, C.2
Troncon, M.G.3
-
28
-
-
0032558285
-
North of England evidence based guideline development project: Summary guideline for non-steroidal anti-inflammatory drugs versus basic analgesia in treating the pain of degenerative arthritis. The North of England Non-Steroidal Anti-Inflammatory Drug Guideline Development Group
-
Aug 22;
-
Eccles M, Freemantle N, Mason J. North of England evidence based guideline development project: summary guideline for non-steroidal anti-inflammatory drugs versus basic analgesia in treating the pain of degenerative arthritis. The North of England Non-Steroidal Anti-Inflammatory Drug Guideline Development Group. BMJ 1998 Aug 22; 317 (7157): 526-30
-
(1998)
BMJ
, vol.317
, Issue.7157
, pp. 526-530
-
-
Eccles, M.1
Freemantle, N.2
Mason, J.3
-
29
-
-
0035112660
-
Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient
-
Feb;
-
Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001 Feb; 120 (3): 594-606
-
(2001)
Gastroenterology
, vol.120
, Issue.3
, pp. 594-606
-
-
Laine, L.1
-
30
-
-
33749536913
-
Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications
-
Hernandez-Diaz S, Garcia Rodriguez LA. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med 2006; 4: 22
-
(2006)
BMC Med
, vol.4
, pp. 22
-
-
Hernandez-Diaz, S.1
Garcia Rodriguez, L.A.2
-
31
-
-
0033598594
-
Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: Population based case-control study
-
Oct 23;
-
de Abajo FJ, Rodriguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ 1999 Oct 23; 319 (7217): 1106-9
-
(1999)
BMJ
, vol.319
, Issue.7217
, pp. 1106-1109
-
-
de Abajo, F.J.1
Rodriguez, L.A.2
Montero, D.3
-
32
-
-
0026548664
-
A chronic disease score from automated pharmacy data
-
Feb;
-
Von-Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992 Feb; 45 (2): 197-203
-
(1992)
J Clin Epidemiol
, vol.45
, Issue.2
, pp. 197-203
-
-
Von-Korff, M.1
Wagner, E.H.2
Saunders, K.3
-
33
-
-
0029351501
-
A chronic disease score with empirically derived weights
-
Aug 1;
-
Clark DO, Von Korff M, Saunders K, et al. A chronic disease score with empirically derived weights. Med Care 2005 Aug 1; 8: 783-98
-
(2005)
Med Care
, vol.8
, pp. 783-798
-
-
Clark, D.O.1
Von Korff, M.2
Saunders, K.3
-
34
-
-
33845608746
-
Use of cyclooxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX-2 cardiovascular profile
-
Dec;
-
Arellano FM, Yood MU, Wentworth CE, et al. Use of cyclooxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX-2 cardiovascular profile. Pharmacoepidemiol Drug Saf 2006 Dec; 15 (12): 861-72
-
(2006)
Pharmacoepidemiol Drug Saf
, vol.15
, Issue.12
, pp. 861-872
-
-
Arellano, F.M.1
Yood, M.U.2
Wentworth, C.E.3
-
35
-
-
0037329150
-
Safety profile of rofecoxib as used in general practice in England: Results of a prescription-event monitoring study
-
Layton D, Riley J, Wilton LW, et al. Safety profile of rofecoxib as used in general practice in England: results of a prescription-event monitoring study. Br J Clin Pharmacol 2002; 55: 166-74
-
(2002)
Br J Clin Pharmacol
, vol.55
, pp. 166-174
-
-
Layton, D.1
Riley, J.2
Wilton, L.W.3
-
36
-
-
5344235403
-
Safety profile of celecoxib as used in general practice in England: Results of a prescription-event monitoring study
-
Sep;
-
Layton D, Wilton LV, Shakir SA. Safety profile of celecoxib as used in general practice in England: results of a prescription-event monitoring study. Eur J Clin Pharmacol 2004 Sep; 60 (7): 489-501
-
(2004)
Eur J Clin Pharmacol
, vol.60
, Issue.7
, pp. 489-501
-
-
Layton, D.1
Wilton, L.V.2
Shakir, S.A.3
-
37
-
-
0035698427
-
Drug switching patterns among patients taking non-steroidal anti-inflammatory drugs: A retrospective cohort study of a general practitioners database in the United Kingdom
-
Oct;
-
Langman M, Kahler KH, Kong SX, et al. Drug switching patterns among patients taking non-steroidal anti-inflammatory drugs: a retrospective cohort study of a general practitioners database in the United Kingdom. Pharmacoepidemiol Drug Saf 2001 Oct; 10 (6): 517-24
-
(2001)
Pharmacoepidemiol Drug Saf
, vol.10
, Issue.6
, pp. 517-524
-
-
Langman, M.1
Kahler, K.H.2
Kong, S.X.3
-
38
-
-
18344390561
-
Are cyclooxygenase-2 inhibitors being taken only by those who need them?
-
May 9;
-
Kaufman DW, Kelly JP, Rosenberg L, et al. Are cyclooxygenase-2 inhibitors being taken only by those who need them? Arch Intern Med 2005 May 9; 165 (9): 1066-7
-
(2005)
Arch Intern Med
, vol.165
, Issue.9
, pp. 1066-1067
-
-
Kaufman, D.W.1
Kelly, J.P.2
Rosenberg, L.3
-
39
-
-
32544433650
-
Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: What is the potential impact of the withdrawal of rofecoxib?
-
Feb 15;
-
Rahme E, Hunsche E, Toubouti Y, et al. Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: what is the potential impact of the withdrawal of rofecoxib? Arthritis Rheum 2006 Feb 15; 55 (1): 27-34
-
(2006)
Arthritis Rheum
, vol.55
, Issue.1
, pp. 27-34
-
-
Rahme, E.1
Hunsche, E.2
Toubouti, Y.3
-
40
-
-
0347418227
-
Determinants of selective cyclooxygenase-2 inhibitor prescribing: Are patient or physician characteristics more important?
-
Dec 15;
-
Solomon DH, Schneeweiss S, Glynn RJ, et al. Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important? Am J Med 2003 Dec 15; 115 (9): 715-20
-
(2003)
Am J Med
, vol.115
, Issue.9
, pp. 715-720
-
-
Solomon, D.H.1
Schneeweiss, S.2
Glynn, R.J.3
-
41
-
-
33749339372
-
Cardiovascular risk and inhibition of cyclooxygenase: A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2
-
Oct 4;
-
McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006 Oct 4; 296 (13): 1633-44
-
(2006)
JAMA
, vol.296
, Issue.13
, pp. 1633-1644
-
-
McGettigan, P.1
Henry, D.2
-
42
-
-
0036208570
-
Contraindicated NSAIDs are frequently prescribed to elderly patients with peptic ulcer disease
-
Feb;
-
Visser LE, Graatsma HH, Stricker BH. Contraindicated NSAIDs are frequently prescribed to elderly patients with peptic ulcer disease. Br J Clin Pharmacol 2002 Feb; 53 (2): 183-8
-
(2002)
Br J Clin Pharmacol
, vol.53
, Issue.2
, pp. 183-188
-
-
Visser, L.E.1
Graatsma, H.H.2
Stricker, B.H.3
-
43
-
-
21044447249
-
The cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: Comparisons, contrasts, and aspirin confounding
-
Jul;
-
Konstantinopoulos PA, Lehmann DF. The cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: comparisons, contrasts, and aspirin confounding. J Clin Pharmacol 2005 Jul; 45 (7): 742-50
-
(2005)
J Clin Pharmacol
, vol.45
, Issue.7
, pp. 742-750
-
-
Konstantinopoulos, P.A.1
Lehmann, D.F.2
-
44
-
-
0037383122
-
Consequences of increased systolic blood pressure in patients with osteoarthritis and rheumatoid arthritis
-
Apr;
-
Singh G, Miller JD, Huse DM, et al. Consequences of increased systolic blood pressure in patients with osteoarthritis and rheumatoid arthritis. J Rheumatol 2003 Apr; 30 (4): 714-9
-
(2003)
J Rheumatol
, vol.30
, Issue.4
, pp. 714-719
-
-
Singh, G.1
Miller, J.D.2
Huse, D.M.3
-
45
-
-
0037196919
-
Case of cholestatic hepatitis with celecoxib did not fulfil international criteria [letter]
-
Mar 30;
-
Arellano FM, Zhao SZ, Reynolds MW. Case of cholestatic hepatitis with celecoxib did not fulfil international criteria [letter]. BMJ 2002 Mar 30; 324 (7340): 789
-
(2002)
BMJ
, vol.324
, Issue.7340
, pp. 789
-
-
Arellano, F.M.1
Zhao, S.Z.2
Reynolds, M.W.3
-
46
-
-
0141729308
-
Approaches to combat with confounding by indication in observational studies of intended drug effects
-
Oct;
-
McMahon AD. Approaches to combat with confounding by indication in observational studies of intended drug effects. Pharmacoepidemiol Drug Saf 2003 Oct; 12 (7): 551-8
-
(2003)
Pharmacoepidemiol Drug Saf
, vol.12
, Issue.7
, pp. 551-558
-
-
McMahon, A.D.1
-
47
-
-
33947219925
-
Characterizing new users of NSAIDs before and after rofecoxib withdrawal
-
Oct 19;
-
Usher C, Bennett K, Teeling M, et al. Characterizing new users of NSAIDs before and after rofecoxib withdrawal. Br J Clin Pharmacol 2006 Oct 19; 63 (4): 494-7
-
(2006)
Br J Clin Pharmacol
, vol.63
, Issue.4
, pp. 494-497
-
-
Usher, C.1
Bennett, K.2
Teeling, M.3
-
48
-
-
33845603062
-
The impact of NSAID or COX-2 inhibitor use on the initiation of antihypertensive therapy
-
Dec;
-
Yood MU, Watkins E, Wells K, et al. The impact of NSAID or COX-2 inhibitor use on the initiation of antihypertensive therapy. Pharmacoepidemiol Drug Saf 2006 Dec; 15 (12): 852-60
-
(2006)
Pharmacoepidemiol Drug Saf
, vol.15
, Issue.12
, pp. 852-860
-
-
Yood, M.U.1
Watkins, E.2
Wells, K.3
-
49
-
-
0033660965
-
Over the counter non-steroidal anti-inflammatory drugs and risk of gastrointestinal bleeding
-
Blot WJ, McLaughlin JK. Over the counter non-steroidal anti-inflammatory drugs and risk of gastrointestinal bleeding. J Epidemiol Biostat 2000; 5 (2): 137-42
-
(2000)
J Epidemiol Biostat
, vol.5
, Issue.2
, pp. 137-142
-
-
Blot, W.J.1
McLaughlin, J.K.2
-
50
-
-
0036732730
-
NSAIDs without a prescription: Over-the-counter access, under-counted risks
-
Sep;
-
Scheiman JM, Fendrick AM. NSAIDs without a prescription: over-the-counter access, under-counted risks. Am J Gastroenterol 2002 Sep; 97 (9): 2159-61
-
(2002)
Am J Gastroenterol
, vol.97
, Issue.9
, pp. 2159-2161
-
-
Scheiman, J.M.1
Fendrick, A.M.2
-
51
-
-
0037149278
-
An evidence-based evaluation of the gastrointestinal safety of coxibs
-
6A, 3D-9D, Mar 21;
-
Bombardier C. An evidence-based evaluation of the gastrointestinal safety of coxibs. Am J Cardiol 2002 Mar 21; 89 (6A): 3D-9D
-
(2002)
Am J Cardiol
, pp. 89
-
-
Bombardier, C.1
-
52
-
-
10844268967
-
Current approaches to prevent NSAID-induced gastropathy: COX selectivity and beyond
-
Dec;
-
Becker JC, Domschke W, Pohle T. Current approaches to prevent NSAID-induced gastropathy: COX selectivity and beyond. Br J Clin Pharmacol 2004 Dec; 58 (6): 587-600
-
(2004)
Br J Clin Pharmacol
, vol.58
, Issue.6
, pp. 587-600
-
-
Becker, J.C.1
Domschke, W.2
Pohle, T.3
-
53
-
-
38549122721
-
-
Former H. NHG-Standpunt over de preventie van NSAID-geinduceerde maagproblemen en de plaats van de coxibs in de huisartpraktijk.2004 [online]. Available from URL: http://nhg.artsennet.nl/content/resources/ AMGATE_6059_104_TICH_L1297846793/AMGATE_6059_104_TICH_R120544452391946// [Accessed 2007 May 1]
-
Former H. NHG-Standpunt over de preventie van NSAID-geinduceerde maagproblemen en de plaats van de coxibs in de huisartpraktijk.2004 [online]. Available from URL: http://nhg.artsennet.nl/content/resources/ AMGATE_6059_104_TICH_L1297846793/AMGATE_6059_104_TICH_R120544452391946// [Accessed 2007 May 1]
-
-
-
-
54
-
-
38549105419
-
-
National Institute of Clinical Excellence. Technology Appraisal No. 27. Guidance on use of cyclo-oxygenase (COXII) selective inhibitors celecoxib, rofecoxib, meloxicam and etodoloac for osteoarthritis and rheumatoid arthritis [online]. Available from URL: http://www.nice.org.uk/nicemedia/pdf/ coxiifullguidance.pdf [Accessed 2001 Aug 1]
-
National Institute of Clinical Excellence. Technology Appraisal No. 27. Guidance on use of cyclo-oxygenase (COXII) selective inhibitors celecoxib, rofecoxib, meloxicam and etodoloac for osteoarthritis and rheumatoid arthritis [online]. Available from URL: http://www.nice.org.uk/nicemedia/pdf/ coxiifullguidance.pdf [Accessed 2001 Aug 1]
-
-
-
-
55
-
-
33845457204
-
Risk of upper gastrointestinal ulcer bleeding associated with selective cyclooxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations
-
Dec;
-
Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclooxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006 Dec; 55 (12): 1731-8
-
(2006)
Gut
, vol.55
, Issue.12
, pp. 1731-1738
-
-
Lanas, A.1
Garcia-Rodriguez, L.A.2
Arroyo, M.T.3
-
56
-
-
0027282451
-
Prescriber profile and post-marketing surveillance
-
Sep 11;
-
Inman W, Pearce G. Prescriber profile and post-marketing surveillance. Lancet 1993 Sep 11; 342 (8872): 658-61
-
(1993)
Lancet
, vol.342
, Issue.8872
, pp. 658-661
-
-
Inman, W.1
Pearce, G.2
-
57
-
-
38549143063
-
-
Cleveland Clinic. Cleveland clinic launches large-scale global trial to examine cardiovascular safety of popular pain relievers. 2006 Dec 13 [online]. Available from URL: http://www.clevelandclinic.org/heartcenter/pub/news/archive/ 2005/painrelief12_13print.htm. [Accessed 2006 Dec 18]
-
Cleveland Clinic. Cleveland clinic launches large-scale global trial to examine cardiovascular safety of popular pain relievers. 2006 Dec 13 [online]. Available from URL: http://www.clevelandclinic.org/heartcenter/pub/news/archive/ 2005/painrelief12_13print.htm. [Accessed 2006 Dec 18]
-
-
-
|